Carboplatin-Etoposide Combination in Hormone-Resistant Prostate Cancers

Inclusion Criteria: * Histological evidence of prostate adenocarcinoma * Metastatic disease, either measurable (lymph nodes, hepatic lesion, pulmonary lesions with longest diameter \> or = 1 cm on spiral scan), or non measurable (bone metastasis) * Patients must: * Have received hormonal therapy via surgical or chemical castration (LH-RH agonist) with or without anti-androgens. Anti-androgen withdrawal is recommended before inclusion, with an off-treatment period of at least 4 weeks. LH-RH agonist treatment must be continued. * Have a relapse or disease refractory to hormonal treatment (defined by a testosterone level \< 0.5 µg/ml) * Have neuroendocrine progression defined, whatever the PSA level, as: * NSE and/or Chromogranin A \> 1.5 x upper limit of normal (ULN) with or without visceral metastases (liver, lung, lymph node) * No increase of NSE or Chromogranin A, but visceral metastases (either hepatic, pleuro-pulmonary, or nodal) with cytological or histological confirmation of the presence of an undifferentiated or neuro-endocrine component of prostatic origin * Prior treatment by radiotherapy is allowed but radiation therapy must have been completed for at least 4 weeks before inclusion and irradiated areas must not represent more than 25% of marrow reserves * Prior treatment by estramustine is allowed but must have been stopped at least 4 weeks before inclusion * Age\> or = 18 years * Life expectancy\> or = 3 months * Karnofsky index\> or = 50% * Adequa…